Effect of BMI Level on Administering Chemotherapy and Adverse Effect of Chemotherapy in Patients with Solid Tumors in Nakornpathom Hospital
Keywords:
body mass index, cancer, chemotherapyAbstract
Objective: This was to determine the effect of BMI level (eg. underweight [BMI < 18.5], normal [BMI 18.5 – 24.9], and overweight [BMI ≥ 25]) on schedule of chemotherapy session and dose of chemotherapy treatment and the adverse effect of chemotherapy on patients with solid tumors in Nakornpathom Hospital.
Methods: A retrospective study was conducted at Nakhonpathom Hospital between June 1, 2018 and December 31, 2018.
Result: There were 246 patients and 64.2% were female. Of total, 90 (36.6%) patients had BMI < 18.5, 115 (46.7%) patients had BMI 18.5 – 24.99, and 41 (16.7%) patients had BMI ≥ 25. Patients with BMI < 18.5 had more delayed chemotherapy, postchemotherapy neutropenia, postchemotherapy anorexia, postchemotherapy weight loss, postchemotherapy fatigue, and postchemotherapy febrile neutropenia than two other groups with statistical significance. Result of multiple logistic regression analysis indicated that important risk factors of postchemotherapy weight loss were neutropenia (OR 2.870, 95% CI 1.339–6.152, p .007) and anorexia (OR 2.297 95% CI 1.020–5.175, p .045).
Conclusion: Low BMI has effect on adverse effect of chemotherapy and dose of chemotherapy treatment in solid tumor patients. We should assess patients’ BMI before starting chemotherapy sessions and immediately provide treatment to patients with low BMI in order to prevent them from developing adverse effect and decreasing dose chemotherapy.
References
Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 2011;12:489–495.
Thoresen L, Frykholm G, Lydersen S, et al. Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin Nutr. 2013;32(1):65–72.
Laviano A, Meguid MM. Nutritional issues in cancer management. Nutrition. 1996;12(5):358–371.
Bruggeman AR, Kamal AH, LeBlanc TW, et al. Cancer Cachexia: Beyond Weight Loss. J Oncol Pract. 2016;12(11):1163–71.
Baracos VE. Management of muscle wasting in cancer-associated cachexia: understanding gained from experimental studies. Cancer. 2001;92(6Suppl):1669–77.
Baracos VE. Cancer-associated cachexia and underlying biological mechanisms. Annu Rev Nutr. 2006; 26:435–61.
National Comprehensive Cancer Network. Antiemesis. Plymouth Meeting: National Comprehensive Cancer Network; 2020.
Bozzetti F. Basics in Clinical Nutrition: Nutritional support in cancer. e-SPEN 2010:e148–52.
Caillet P, Liuu E, Simon AR, et al.Association between cachexia, chemotherapy and outcomes in older cancer patients: A systematic review. Clin Nutr. 2017;36(6):1473–82.
Caro MMM, Laviano A, Pichard C, et al. Nutritional intervention and quality of life in adult oncology patients. Clin Nutr. 2007;26(3):289–301.
Pin F, Couch ME, Bonetto A, et al. Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition.Curr Opin Support Palliat Care. 2018;12(4):420–426.
Takeda T, Sasaki T , Suzumori C. The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy. Int J Clin Oncol. 2021;26(7):1293–1303.
Dev R. Measuring cachexia-diagnostic criteria. Ann Palliat Med. 2019;8(1):24–32.
Grabowski JP, Richter R, Rittmeister H, et al. Impact of Body Mass Index (BMI) on Chemotherapy-associated Toxicity in Ovarian Cancer Patients. A Pooled Analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) Databank on 1,213 Patients. Anticancer Res. 2018;38(10):5853–8.
Saleh K, Carton M, Dieras V, et al. Impact of body mass index on overall survival in patients with metastatic breast cancer. Breast. 2021;55:16–24.
Shepshelovich D,Xu W, Lu L, et al. Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium. J Thorac Oncol.2019;14(9):1594–1607.
Shahjehan F, Merchea A, Cochuyt J, et al. Body Mass Index and Long-Term Outcomes in Patients With Colorectal Cancer. Front Oncol. 2018;8:620.
Cha B, YU JH, Jin YJ, et al. Survival Outcomes According to Body Mass Index in Hepatocellular Carcinoma Patient: Analysis of Nationwide Cancer Registry Database.Sci Rep. 2020;10:8347.
Greenlee H, Unger JM, Hershman DL, et al. Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials. Cancer Epidemiol Biomarkers Prev. 2017;26(1):21–29.
Medical Dictionary Regulatory Activities. Common terminology criteria for adverse events (CTCAE) Washington, D.C.: U.S. Department of Health and Human Services; 2017.
Fearon K, Arends J, Baracos V. Understading the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013;10(2):90–9.
Martin L, Senesse P, Gioulbasanis T, et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 2015;33(1):90–9.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ลิขสิทธิ์บทความเป็นของผู้เขียนบทความ แต่หากผลงานของท่านได้รับการพิจารณาตีพิมพ์ลงวารสารแพทย์เขต 4-5 จะคงไว้ซึ่งสิทธิ์ในการตีพิมพ์ครั้งแรกด้วยเหตุที่บทความจะปรากฎในวารสารที่เข้าถึงได้ จึงอนุญาตให้นำบทความในวารสารไปใช้ประโยชน์ได้ในเชิงวิชาการโดยจำเป็นต้องมีการอ้างอิงถึงชื่อวารสารอย่างถูกต้อง แต่ไม่อนุญาตให้นำไปใช้ในเชิงพาณิชย์
